Literature DB >> 12570115

The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics.

D Sherrill1, S Guerra, A Bobadilla, R Barbee.   

Abstract

Several recent reports have presented evidence suggesting that adults with asthma have an accelerated rate of decline in pulmonary function compared with nonasthmatics. However, most of these studies have not taken into account the possible effect of comorbid lung disease in addition to asthma. This study was designed to determine if comorbid respiratory diseases modify or otherwise change the estimates of decline in forced expiratory volume in one second (FEV1). Study subjects were White, non-Mexican, American participants, who were > or = 20 yrs of age at the initial survey and had at least one pulmonary function testing. Respiratory disease status, based on self-reported questionnaires and pulmonary function tests, were assessed during 12 surveys spanning a period of up to 20 yrs. There were 2,926 subjects who met the inclusion criteria, 214 (7.3%) had physician-confirmed asthma, 325 (11.1%) chronic obstructive pulmonary disease (COPD), and 125 (4.3%) both physician-confirmed asthma and COPD. Longitudinal analysis revealed that among those with longstanding asthma, FEV1 values were low but did not decline at a more rapid rate than normal. Likewise, subjects with both asthma and COPD had the lowest levels of FEV1, but also a rate of decline that was not significantly increased. Only those with COPD in the absence of asthma experienced both a low initial FEV1 level and a significantly steeper rate of decline. Based on these findings, the authors conclude that forced expiratory volume in one second does not decline more rapidly in asthmatics or in those with asthma and chronic obstructive pulmonary disease, compared with nonasthmatics.

Entities:  

Mesh:

Year:  2003        PMID: 12570115     DOI: 10.1183/09031936.03.00017103

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Pulmonary function after exposure to the World Trade Center collapse in the New York City Fire Department.

Authors:  Gisela I Banauch; Charles Hall; Michael Weiden; Hillel W Cohen; Thomas K Aldrich; Vasillios Christodoulou; Nicole Arcentales; Kerry J Kelly; David J Prezant
Journal:  Am J Respir Crit Care Med       Date:  2006-04-27       Impact factor: 21.405

2.  Year-to-year changes in lung function in individuals with cystic fibrosis.

Authors:  Theodore G Liou; Eric P Elkin; David J Pasta; Joan R Jacobs; Michael W Konstan; Wayne J Morgan; Jeffrey S Wagener
Journal:  J Cyst Fibros       Date:  2010-05-14       Impact factor: 5.482

Review 3.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial.

Authors:  Neil C Thomson; Adalberto S Rubin; Robert M Niven; Paul A Corris; Hans Christian Siersted; Ronald Olivenstein; Ian D Pavord; David McCormack; Michel Laviolette; Narinder S Shargill; Gerard Cox
Journal:  BMC Pulm Med       Date:  2011-02-11       Impact factor: 3.317

5.  Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma.

Authors:  David L Hahn; Mary Beth Plane; Olaimatu S Mahdi; Gerald I Byrne
Journal:  PLoS Clin Trials       Date:  2006-06-30

6.  Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life.

Authors:  Sapna Bhatia; Clifford Qualls; Thomas A Crowell; Alexander Arynchyn; Bharat Thyagarajan; Lewis J Smith; Ravi Kalhan; David R Jacobs; Holly Kramer; Daniel Duprez; Bartolome Celli; Akshay Sood
Journal:  BMJ Open Respir Res       Date:  2017-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.